Kryptoscan

Krypton-81m, the active ingredient in Kryptoscan, is a medical gas presented as a medical gas for Inhalation use. It is used for diagnostic imaging of the lungs in adult patients. GNH USA supplies Kryptoscan as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Kryptoscan (Krypton-81m) is employed in nuclear medicine for pulmonary ventilation imaging.

Ventilation imaging: provides functional assessment of pulmonary air distribution. Pulmonary function assessment: aids in evaluating regional lung ventilation defects. Research applications: used in clinical studies investigating respiratory physiology.

Kryptoscan may cause transient reactions related to inhalation and radiation exposure.

Common Side Effects: - Mild cough or throat irritation - Shortness of breath during administration - Nausea or mild headache - Dizziness or light‑headedness - Taste alteration - Transient facial flushing

Serious or Rare Side Effects: - Radiation‑induced tissue injury - Allergic reaction or anaphylaxis - Bronchospasm or severe airway constriction - Pulmonary edema - Radiation‑related malignancy risk (theoretical) - Severe hypotension

Kryptoscan requires careful handling and patient assessment before use.

Pregnancy: avoid unless essential, due to radiation exposure. Breastfeeding: contraindicated, as the isotope may be transferred to infant. Respiratory disease: evaluate risk in patients with asthma or COPD. Radiation safety: follow institutional protocols to limit exposure. Concurrent imaging: schedule to prevent overlapping radiopharmaceuticals. Store at ambient temperature: keep cylinder in original container, protect from heat and direct sunlight.

Kryptoscan may interact with other agents that affect lung function or radiation exposure.

Major Interactions (Avoid): - Concurrent radiopharmaceuticals: overlapping imaging can compromise diagnostic accuracy. - High‑dose bronchodilators administered immediately before inhalation: may alter gas distribution.

Moderate Interactions (Monitor Closely): - Beta‑agonist inhalers: monitor ventilation patterns. - Anticholinergic agents: assess for additive respiratory effects. - Sedatives or opioids: watch for respiratory depression. - Supplemental oxygen therapy: may dilute inhaled gas concentration.